Certolizumab pegol (Cimzia ®) for moderate to severe plaque psoriasis

Assessment Status Rapid Review complete
Drug Certolizumab pegol
Brand Cimzia®
Indication For the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
Assessment Process
Rapid review commissioned 14/10/2019
Rapid review completed 14/11/2019
Rapid review outcome A full HTA is not recommended. The NCPE recommends that certolizumab pegol not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.